Clinical trials
Advanced Malignant Cancer clinical trials
Below are recruiting advanced malignant cancer clinical trials, each written for real people, not researchers. We’re tracking 1,517 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT07426757RecruitingPhase 1
A study of PF-07994525 for advanced multiple myeloma
This trial tests an experimental drug, PF-07994525, for people with advanced multiple myeloma that has not responded to or could not tolerate at least 3 prior treatments. The goal is to see if it can help control the cancer.
Denver, ColoradoAges 18 years+ - NCT07434284RecruitingEarly Phase 1
Cell therapy plus immunotherapy for advanced gynecologic cancers
This trial is testing a new combination treatment for advanced gynecologic cancers (like ovarian, cervical, or endometrial) that have not responded to standard therapies. It combines a type of cell therapy (cCTL) with another immunotherapy to see if it can help patients who have few other options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07431073RecruitingPhase 2
Immunotherapy master trial for advanced cancers
This trial tests different immunotherapy treatments for people with advanced cancer that has spread or cannot be removed by surgery. It aims to find out which treatments work best by studying your tumor and blood samples over time.
VillejuifAges 12 years+ - NCT06717880RecruitingPhase 1
Combination therapy for advanced colorectal cancer
This trial tests a new drug (IBI363) combined with either bevacizumab or furuitinib for people with advanced colorectal cancer that has worsened after standard treatments. It aims to find a more effective option for those who have limited alternatives.
Wuhan, HubeiAges 18–75 - NCT07408505Recruiting
New appetite drug for weight loss in advanced pancreatic cancer
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
JinanAges 18–75 - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07389239RecruitingPhase 1/Phase 2
Immunotherapy for ovarian cancer and other advanced tumors
This study tests an immunotherapy treatment for people with advanced solid tumors, including ovarian cancer, sarcoma, prostate, breast, lung, and others. It is designed for tumors that show a specific marker called NY-ESO-1, and aims to see if the treatment can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07337525RecruitingPhase 1
First study of PLT012 in advanced solid tumors
This trial tests a new drug called PLT012 for people with advanced solid tumors. It is the first study in humans, so doctors will see if the drug is safe and how the body handles it.
Los Angeles, CaliforniaAges 18 years+ - NCT07340190RecruitingPhase 1
How pelabresib affects other drugs in advanced cancer
This study tests how a new drug (pelabresib) interacts with other medicines like diabetes pills, a sedative, and birth control pills. It is for people with advanced cancer to help understand safe dosing.
BordeauxAges 18 years+ - NCT07326137Recruiting
Pain relief and first-line treatment for advanced bile duct or pancreatic cancer
This study tests combining standard first-line cancer therapy with a nerve block to reduce pain in people with advanced bile duct or pancreatic cancer. It aims to see if this combination can improve pain control and quality of life.
Wuhan, HubeiAges Any age - NCT07321106RecruitingPhase 1
CBI-1214 for advanced colorectal cancer
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Hot Springs, ArkansasAges 18–55 - NCT07306559RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
Los Angeles, CaliforniaAges 18 years+ - NCT07269145RecruitingPhase 1
Testing TQB3122 capsules in advanced solid tumors
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07260708RecruitingPhase 1
Study of TQB2922 injection for advanced lung cancer
This study tests an investigational drug called TQB2922, given as an injection under the skin, for people with advanced non-small cell lung cancer that has not improved with standard treatments. The goal is to see if the drug is safe and helpful.
Beijing, Beijing MunicipalityAges 18–75 - NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+ - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT06188624RecruitingPhase 1
Study of TQB2922 for advanced cancers
This trial tests a new drug, TQB2922, for people with advanced cancers that have not responded to standard treatments. The goal is to see if it is safe and how it affects the cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07190469RecruitingPhase 1
PQ203 for advanced solid tumors like triple-negative breast cancer
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Houston, TexasAges 18 years+ - NCT07174661Recruiting
Planning ahead for teens and young adults with advanced cancer
This study tests an educational tool to help young adults with advanced solid tumors or high-grade brain tumors think about and discuss their future healthcare wishes early. It may help you feel more prepared and in control of your care.
Scottsdale, ArizonaAges 18–39
Hear when a new Advanced Malignant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant cancer?
- Yes. Clin2 currently lists 1,517 recruiting advanced malignant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.